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Abstract Objectives: The purpose of this study was to evaluate the safety and efficacy of the ASDOS-tech-
nique (Sulzer-Osypka GmbH, Germany) for transcatheter closure of atrial septal defects within the oval
fossa.
Background: Although several attempts have been made to occlude defects within the oval fossa by tran-
scatheter techniques, none of these has gained general acceptance.
Methods: Patients with a defect in the oval fossa measuring equal to or less than 20 mm diameter, with a
residual septal rim of 5mm or greater, body weight greater than 10 kg, with clinical indications for surgical
closure were considered for transcatheter closure. Follow-up investigations were performed at discharge,
after 1, 3, 6 and 9 months, as well as after 1 and 2 years.
Results: Of 78 patients considered for closure, a device was inserted in 41 patients (53%), with success
being achieved in 40 patients (98%). The ages ranged from 1.1 to 15 years (7.8 ± 1.92 years), the
'stretched' diameter of the defect from 10 to 20 mm (14.7 ± 2.60 mm), and the diameters of the inserted
devices from 25 to 45 mm (33.2 ± 5.43 mm). Transient impairment of atrioventricular conduction occured
in 4 patients. During the follow-up of 23.0 ± 5.6 months elective surgical closure of a residual shunt was
performed 26 months after insertion of the devcie in one patient. None of the other patients required sur-
gery, hospitalisation or medical treatment, and none is requiring further treatment of the defect within the
oval fossa. Fracture of one arm of the device occurred in 4 patients, but the fractured arms are in an
unchanged and stable position after a period of at least 19 months.
Conclusions: Our medium-term data show that transcatheter closure in children of defects within the oval
fossa can be performed with a high efficacy and safety using the ASDOS-device.
Keywords: Atrial septal defect, interventional cardiology, closure devices, biomaterials.
THE SURGICAL CLOSURE OF ATRIAL SEPTALdefects has, today, a negligable mortalityand is still the procedure of choice.1'2 It is,
however, associated with a significant morbidity
and risks inherent to the surgical techniques
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itself, including thoracotomy, cardiotomy and the
need for extracorporal circulation.2 Although fur-
ther refinements of the surgical techniques have
been developed,3'4 several attempts have been
made to occlude defects in the oval fossa by tran-
scatheter techniques as an alternative approach.5"
15
 Up to now, none of these techniques has gained
general acceptance. The ASDOS-technique
(ASDOS = Atrial-Septal-Defect-Occlusion-System;
Sulzer-Osypka GmbH, Germany) was described
originally by Babic.1214 The device consists of
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two separate umbrellas which are connected by a
screwing mechanism and are thereby firmly
attached to the rims of the deficient oval fossa
(Fig.l). The device can be retrieved transve-
nously and repositioned after unscrewing both
umbrellas.14 In this report, we present our
medium-term results (76.8 patient-years of fol-
low-up) in 40 children in whom the device was
inserted to close an atrial septal defect in the oval
fossa, all patients having suitable indications for
surgical closure.
Patients and methods
Between January 1995 and July 1996, 78 children
with atrial septal defects in the oval fossa were con-
sidered for transcatheter closure using the ASDOS-
technique at five institutions (Charite-Berlin
(Germany); Universitatsklinik Essen (Germany);
Christian Albrechts Universitat , Kiel (Germany);
Guy's Hospital, London (UK); University
Hospital, Geneva (Switzerland)). Only patients
with a defect in the oval fossa and normal pul-
monary resistance, a body weight greater than 10
kg and clinical indications for surgical closure were
considered for transcatheter intervention. For
preinterventional imaging, transthoracic or trans-
esophageal echocardiography was performed to
measure the maximal diameter of the atrial septal
defect and the minimal rim of tissue surrounding
the defect. Additionally, the maximal 'length' of
the residual interatrial septum was measured in the
transthoracic echocardiogram from the apical four-
chamber-view taking the distance between the sep-
tal insertion of the mitral valve to the origin of the
right upper pulmonary vein as an estimate for the
largest device which could be implanted. Only
patients with a ratio between the diameter of the
defect and the measured length of the interatrial
septum of less than 2 were included.
Study protocol
The device was released for a limited clinical trial
according to a study protocol approved by the
authorized human subjects committee and by the
local governmental authorities according to the
european regulatory body for the approval of
implantable devices. The study protocol was
designed according to the declaration of Helsinki
in its revised form of Tokyo. Informed consent was
obtained from the patients, or the guardians,
before implantation was attempted.
Criterions for inclusion into the study as
obtained during cardiac catheterization were:
• Atrial septal defect within the oval fossa with
normal pulmonary resistance
• Indication for surgical closure of the defect (pul-
monic-to-systemic flow ratio greater than 1.5)
• Body weight greater than 10 kg
• Defect diameter less than 20 mm, residual rim
greater than 5mm
• No major associated disease, which could inter-
fere with implantation of the device.
Description of the device
The ASDOS-device (Sulzer-Osypka GmbH,
Germany) basically consists of two umbrellas
which are introduced into the left and right atrium
over a guidewire-looped from the femoral vein to
the femoral artery. The device, and the technique of
implantation have been described previously in
detail.14 Briefly, both umbrellas consist of a central
body and five arms, which are made of preshaped
nitinol-wire, and are covered by a thin
Figure 1.
The ASDOS-Device is shown en face (a) and en profile (b) after connecting the two umbrellas. The arms of the device which are made out of
curved nitinol and covered by a thin polyurethan patch.
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S1047951100007125
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 21:32:37, subject to the Cambridge Core terms of use, available at
464 Cardiology in the Young October 1998
polyurethane-patch. The central body of the distal
(left atrial) umbrella contains a thread, while the
proximal (right atrial) umbrella contains a bolt
(Fig.la). Both umbrellas are inserted into the left
and right atrium separately, and are connected by
screwing the bolt on the threat using a screwdriver
catheter (Fig.lb). Both umbrellas have a rounded
shape due to the configuration of the five arms
(Fig.la). In subsequent descriptions the diameter
at the tips of the arms will be referred to as the
diameter of the device.
Technique of implantation
During cardiac catheterization, anomalous
drainage of the pulmonary veins was excluded by
right ventricular and, if necessary, by selective pul-
monary angiography. The pulmonic-to-systemic-
flow ratio was calculated from the oxymetric data.
The 'stretched' diameter of the defect was assessed
by balloon sizing using a compliant balloon
catheter (modified Berman-catheter, special
request, Arrows; occlusion balloon, Boston
Scientific). The sizing balloon was advanced into
the left atrium, slowely inflated, and pulled back to
the interatrial septum. Using transthoracic or
transesophageal colour-coded-doppler echocardio-
graphy, the smallest diameter was measured at the
point where were the left-to-right-shunt ceased. In
addition, the maximal diameter of the balloon
which passed through the defect was measured.16"18
For the implantation of the ASDOS-device, a
guidewire was looped from the femoral vein
through the atrial septal defect to the femoral
artery using a 0.014-in nitinol guidewire with a
O.O35-in conus at its middle (450 cm, ASDOS-
guidewire, Osypka-Sulzer GmbH, Germany). This
lopp was immediately covered by a catheter (4F
modified right Amplatz, Cordis) to protect the aor-
tic and mitral valvar leaflets. An 11F long sheath
was inserted over the guidewire into the femoral
vein and its tip advanced into the left atrium. The
diameter of the device was selected so that it dou-
bled the diameter of the defect. The distal (left
atrial) and proximal (right atrial) umbrellas were
than inserted over the guidewire through this long-
sheath. The left atrial umbrella was advanced using
a 'pusher' (metalic 22G cannula with rounded tip)
and retrieved by the conus on the guidewire-track.
The right atrial umbrella was controlled by the
screwdriver catheter, which was hooked into the
thread by a counterclockwise rotation (Fig.2a).
Cross-sectional echocardiography was performed
to position the umbrellas on either side of the atrial
septum, and color-coded-doppler echocardiogra-
phy used to confirm cessation of left-to-right
shunting across the atrial septal defect. To connect
the umbrellas, the nitinol loop and screwdriver
catheter were used to advance the bolt into the
thread. Thereafter the screwdriver catheter was
rotated clockwise, screwing the bolt firmly on the
thread (Fig.2b). Adequate screwing was confirmed
by observing the decreasing distance between the
two umbrellas. Finally, complete closure of the
atrial septal defect, normal flow within the sys-
temic and pulmonary veins, competence of the
atrioventricular valves, as well as an adequate posi-
tion of the umbrellas on both sides of the atrial sep-
tum, was confirmed by echocardiography before
relaesing the device by pulling the nitinol-wire
throught the arterial catheter and out of the
patient (Fig.2c).
Medication during and after implantation
Following the procedure heparin, was administered
intravenously by continous infusion. Within the
first 24 hours, 600 IU/kg heparin were adminis-
tered. During the second 24 hours 400 IU/kg was
given and than 200 IU/kg for an additional 24
hours. The antithrombin III levels were kept above
90%. Cefuroxim 50 mg/kg was administered in
two doses 6 and 12 hours after termination of the
procedure. Aspirin 2 to 3 mg/kg daily and dipyri-
damol 2 to 3 rng/kg daily were administered orally
for 6 months thereafter. Endocarditis prophylaxis
was recommended for 12 months.
Follow-up investigations
Follow-up investigations were performed at all par-
ticipating centers at discharge, after 1, 3, 6 and 9
months, as well as after 1 and 2 years. Follow-up
investigations included clinical examination, stan-
dard electrocardiograms, transthoracic echocardio-
graphy, chest X-ray or fluoroscopy, and Holter
monitoring. A residual shunt was classified as sig-
nificant if it was greater than 2 mm as judged in
the color-coded-doppler-echocardiogram, trivial if
it was less than 2 mm, and as turbulance, if a flow
disturbance was visible near the device which could
not clearly be defined as trivial shunting.
Statistics
Students-t-test was performed for statistical com-
parisons between means.
Results
From January 1995 to July 1996, 78 patients were
considered for closure using the ASDOS technique
after screening with transthoracic or transesophageal
echocardiography. During diagnostic cardiac
catheterization and sizing of the defect, 37 patients
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Figure 2.
Implantation of the ASDOS-Device.
a. The two umbrellas have been delivered on either side of the intera-
trial septum.
b. The umbrellas have been connected by screwing the bolt of the right
atrial umbrella on the threat of the left atrial umbrella. Note the
change of shape of both umbrellas before and after connecting them.
c. Transesophageal echocardiogram after release of the device, the
device is firmly attached to the rims of the oval fossa.
(47%) were excluded from the study and no attempt
was made interventionally to close the defect. The
reasons for withdrawal of these patients from the
study are summarized in Table 1. All of the patients
requiring surgical closure were discharged the day
after the cardiac catheterization, and were subse-
quently scheduled for elective surgical closure.
Transcatheter closure of the defect was attempted in
41 patients (53%). The age of these patients ranged
from 1.1 to 15 years (7.8 ± 1.92 years), the body
weight varied from 11 to 56 kg (27.6 ± 12.65 kg).
The diameter of the defect ranged from 8 to 22 mm
(13-4 ± 3-33 mm) as judged in the echocardiogram,
while the 'stretched' diameter evaluated during bal-
loon sizing ranged from 10 to 20 mm (14.7 ± 2.60
mm) (Table 2). Thus, the 'stretched' diameter was
significantly larger (p < .0005) than the estimated
echocardiographic diameter. The ratio of pul-
monary-to-systemic blood flow varied from 1.5:1 to
3.0:1 (1.9 ± 0.35), while the ratio of pulmonary-to-
systemic resistance was lower than 0.015:1 in all
patients. Mild Ebstein's malformation of the tricus-
pid valve without relevant tricuspid regurgitation
was an associated finding in one patient. In another
patient a small ('silent') arterial duct was found,
which was occluded using a coil. General anesthesia
was performed in 58 of the children for trans-
esophageal echocardiography.
Immediate results
Successful implantation of the device was achieved
in 40 of 41 patients (98%) in whom implantation
was attempted. The size of the implanted devices
ranged from 25 to 45 mm (33.2 ± 5.43 mm). The
ratio of diameters of device to defect varied from
1.76 to 3.33 (2.3 ± 0.28) (Table 2). The 'length' of
the interatrial septum as measured in the apical
four-chamber-view was between 29 mm and 50
mm (37.7 ± 6.14 mm). The ratio between this
measurement and the diameter of the device
ranged from 0.91 to 2.0 (1.14 ± 0.19). All
patients had a residual rim of atrial tissue of more
than 5 mm (range 5 to 12 mm; 7.55 ± 1.92 mm).
Occlusion of the defect with the initially selected
device was successful in 36 of 41 patients (88%). In
4 patients, the device had to be retrieved and
exchanged for a larger (n = 3) or smaller (n = 1)
device, which was subsequently used successfully
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Table 1. Reasons to withdraw patients from the study (37/78
patients)
Multiperforated and floppy interatrial septum n = 4
'Stretched' defect size greater than 20 mm n = 5
additional partial anomalous pulmonary venous return n = 5
Rim of oval fossa less than 5 mm n = 4
Pulmonary-to-systemic flow ratio < 1.5:1 n = 6
Defect size larger than 50% of the interatrial length n = 13
Table 2. Implantation data
Mean SD Range
Echocardiographic
Diameter (maximal)
'Stretched' Diameter
Atrial Length
Minimal Rim
Diameter of Device
13.4 mm 3-3 mm 8 to 22 mm
14.7 mm 2.6 mm 10 to 20 mm
37.7 mm 6.1mm 29 to 50 mm
7.6 mm 1.92 mm 5 to 12 mm
44.3 mm 5.43 mm 25 to 45 mm
Ratio of Device to Defect 2.3 0.28 1.76 to 3.3
for closure. Retrieval of the device was performed
transvenously without complications. In all but
one patient, the same venous access was used for
the definitive closure of the atrial septal defect. In
only one of 41 patients (2.4%) had the procedure
to be abandoned. This was because complete clo-
sure of the defect could not be achieved with a 35-
mm device, and a 40-mm device seemed not to fit
into the atriums.
In none of the patients a significant shunt (greater
than 2 mm) was observed after the procedure. A
trivial residual shunt (less than 2 mm) was visible by
colored-doppler-echocardiography in 4 of 40
patients immediately after closure. A turbulance
near the device, which could not be clearly classified
as a minimal residual shunt or disturbed flow due to
the device, was observed in 5 additional patients
(Table 3). The procedure time ranged from 67 min
to 425 min (173 ± 99 min), the fluoroscopic time
from 15.3 min to 77 min (36 ± 1 7 min).
Complications before discharge
In none of the patients did we encounter complica-
tions leading to death, surgery, morbidity or med-
ical treatment other than treatment according to
the study protocol. Transient impairment of atri-
oventricular conduction occured in 3 patients dur-
ing the procedure, which normalized immediately
after unscrewing both umbrellas and repositioning
the device without acute or late sequels. Air
embolism, thromboembolism or bleeding necessi-
tating transfusion were not observed during or
after the procedure. Transient deterioration of atri-
oventricular conduction occurred in one patient 6
hours after implantation. Brief periods of second
and third degree atrioventricular block were
noticed in this patient within the first three days
following the implantation. As a stable escape
rhythm with narrow QRS-complexes was present
all the time, no specific therapy was required.
Atrioventricular conduction normalized within 3
days. Repeated Holter-monitoring and standard-
electrocardiograms revealed normal atrioventricu-
lar conduction with a PR-interval of 170 msec dur-
ing a follow-up period of 26 months. In one
additional patient, a small pericardial effusion was
observed 3 days after the implantation, which
required no therapy and resolved spontaneously
within 4 weeks. The etiology remains speculative,
as no diagnostic puncture of the effusion was per-
formed.
Follow-up data
Duration of follow-up of the 40 patients with suc-
cessful implantation of the device ranges from 13
to 32 months (23.0 ± 5 . 6 months). All patients
have been followed for at least 12 months. The
cumulative follow-up period is 921 patient-
months, or 76.8 patient-years. In one patient with
a residual shunt, elective surgical closure was per-
formed 26 months after the initial intervention.
None of the other patients required surgery, hospi-
talisation or a medical treatment other than endo-
carditis prophylaxis or supportive treatment for
common cold. In none of the patients did we
observe arrhythmias, thromboembolism, endo-
carditis, death, morbidity or other disorders. Trivial
residual shunting was observed in one patient at 12
months follow-up. In another 4 patients flow dis-
turbance near the device, which could not be dif-
ferentiated from a minimal shunt, was detected
echocardiographically. At 24 months follow-up
only one patient had a trivial shunt. Surgical clo-
sure was performed after 26 months in this patient
to achieve definite closure of the residual defect and
exclude the risk for endocarditis. The device was
completely covered by tissue. In none of the other
patients is there any indication for further treat-
ment of the atrial septal defect.
Fracture of one arm of the device occurred in 4
patients within the first 3 months after implanta-
tion (Fig. 3). No predeliction site was found for
fractures. Two of them occurred at 4 o'clock, one at
9 o'clock and one at 7 o'clock in the en-face view.
In all these patients, the fractured arms are still in
an unchanged and stable position after 29, 27, 21
and 19 months respectively. In none of these
patients did we observe residual shunting or distur-
bance in flow. The fractures were not visible in the
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standard chest X-ray. Starting in April 1995, there-
fore fluoroscopic control of the integrity of the
device was routinely performed. All fractures
occurred within the first three months after the
implantation.
The right ventricular internal diameter, as meas-
ured in the M-Mode echocardiogram, was 21.3 ±
6.0 mm before occlusion of the defect. 6 months
after closure it had decreased by 27.8 ± 18.0% to
15.5 ± 4.7 mm (p < .0001) (Table 4). At 1 year fol-
low-up, the right ventricular internal diameter was
17.7 ± 5.2 mm. Although this is still significantly
smaller than the diameter prior to implantation (p
< .0001), there is a slight increase when compared
with the diameter noted at 6 months-follow-up
(n.s.). When the right ventricular diameter is 'cor-
rected' for overall growth of the patient by calculat-
ing the ratio of right ventricular to left ventricular
Figure 3.
Fluoroscopy of a fractured device after 3 months of follow-up.
Although fractures of arms are a matter of concern, the fragment and
the device are in stable and unchanged position for at least 19 months.
Although there seems to be dislocation of one arm, this reflects a 'thick'
interatrial septum in this particular patient.
end-diastolic diameters, this ratio was .64 ± .18
before implantation, .44 ± .17 at 6-months follow-
up (p < .0001) and .47 ± .17 (p < .0001) at 1-year
follow-up. In none of the patients was paradoxical
septal motion observed after occlusion of the defect.
Discussion
Transcatheter closure of defects in the oval fossa is a
promising approach for at least some patients, as
thoracotomy, cardiotomy and extracorporal circu-
lation with ischemia of the heart can all be avoided.
In this series we considered 78 patients for tran-
scatheter closure, attempted closure in 41 patients,
and achieved success 40 patients. Thus, in 53% of
the preselected patients, and in 98% of patients in
whom transcatheter closure was attempted, the
atrial septal defect was occluded. Although the rate
of successfull closure was high in those patients, in
which it it had been attempted, we were able to
achieve closure in only every second patient ini-
tially considered. Although a suboptimal preselec-
tion of patients cannot be excluded, another reason
for this low rate of implantation was the caution of
the investigators not to use oversized devices which
might have resulted in friction lesions, or even per-
foration of the atrial wall, due to the stresses
between the device and the walls of the heart. In
only one of these patients was elective surgical clo-
sure needed because of a residual shunt. In none of
the other patients was further treatment required
related to the atrial septal defect within a cumula-
tive follow-up of 76.8 patient-years. The right ven-
tricular diameter decreased significantly after
successfull closure (Table 4). Potential complica-
tions, such as embolization or dislocation of the
device,7'19"23 thromboembolic complications, endo-
carditis, pericardial effusion due to perforation or
pressure necrosis,21'22 tricuspid or mitral regurgita-
tion,7'24 alteration of venous return or significant
residual shunting did not occur in this initial series.
This lack of significant complications seems to be
noteworthy when compared to other reports.21'22
We speculate, that this may be due to the careful
Table 3. Residual shunt after transcatheter closure using the ASDOS-Device.
n =
none
turbulance
trivial ( < 2mm)
significant ( > 2 mm)
Implantation
40
31
5
4
0
Discharge
40
32
5
3
0
6 months
40
34
5
1
0
1 year
40
36
4
1
0
2 years
19
17
2
1
0
Abbreviations: Implantation — immediately after implantation; Discharge — at discharge from hospital; 3,6 and 12 months -
months after implantation.
3, 6 and 12
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Table 4. Change of echocardiographic right and left ventricular diameters 6 and 12 months after transcatheter closure using the
ASDOS-device (n = 32).
Before ASD-closure 6 months follow-up 12 months follow-up
RVID (mm)
LVID (mm)
RVID/LVID
21.3 ± 6.0
34.3 ± 5.7
0.64 ± 0.18
27.8 ± 18.0***
37.0 ± 6.6**
0.44 ± 0.17***
17.7 ± 5.2***
38.2 ± 5.2**
0.47 ± 0.17***
Abbreviations: RVID - diastolic right ventricular internal diameter (M-mode); LVID - diastolic left ventricular internal diameter (M-
mode); * p<.01; ** p<.001; *** p<.0001
selection of patients, and strict adherence to the
study protocol. Significant residual shunting was
not observed in any patient, while trivial shunting
being observed in only one by colored-doppler-
echocardiography after 12 and 24 months of follow
up (Table 3).
For successful transcatheter closure with this
technique it seems necessary to have an adequate
rim of tissue surrounding the oval fossa as the
implanted device has to cover not only the defect
but also its rims to obtain a firm attachment and
produce secure occlusion of the defect.17'18'25-26 A
firm attachment of the device to the margins of the
oval fossa seems to be of additional importance for
complete endothelization of the device, which
starts at the site where the rims of the device are in
conjunction with the atrial walls.8'10'11'13 In this
series, the residual rim ranged from 5 to 12 mm
(7.55 ± 1.92 mm) (Table 2). The ratio between the
measured length of the interatrial septum and the
maximal diameter of the device ranged from 0.91
to 2.0 (1.14 ± 0.19), indicating that, in most
patients (median 1.1), the device covered the oval
fossa almost completely (Table 2). The device was
usually twice the diameter of the defect with a ratio
of 2.3 ± .28 (median 2.3). During this series, no
attempt was made to use smaller devices. The
device itself is not self-centering, but repositioning
can be achieved by use of the guidewire and the
individually preshaped pusher. Careful reposition-
ing of the device under echocardiographic guidance
was necessary in the majority of our patients to
achieve adequate positioning and complete occlu-
sion. Echocardiography allows the precise assess-
ment of the position of the device within the oval
fossa, and its relation to adjacent structures as the
pulmonary and systemic veins, the eustachian and
atrioventricular valves, as well the ascending aorta
and the triangle of Koch containg the atrioventric-
ular node. Thus, in contrast to self-centering
devices, where the self-centering mechanism
defines the final position of the device, the
ASDOS-technique permits positioning and reposi-
tioning as determined by the operator.
The diameter of the implanted devices varied
from 25 to 45 mm. For the implantation of such
large devices it is important to be able to retrieve
the device transvenously without the need for sur-
gery.20 Retrieval was needed in 4 patients, because
it was obviously too small, while in one patient it
was too large to fit into the atriums. Retrieval of all
devices was performed interventionally without
complications, as previously described.14 Due to
the 'memory' of the nitinol arms, the devices were
intact after retrieval. In three of these patients,
complete occlusion of the defect was subsequently
achieved after implantation of a larger device, in
one patient after implantation of a smaller device,
while in the other patient the attempted tran-
scatheter closure was abandoned because the defect
seemed to be unsuitable. The option to release the
device from the delivery system while still on the
guidewire circuit seems to be an advantage of the
ASDOS-technique, as the adequate position of the
device can be controlled, while repositioning and
retrieval is still possible.Due to the tension
between the guidewire circuit and the device, 'triv-
ial' shunting between the tips of the arms was
observed immediately prior to release in several
patients. After release from the guidewire circuit
this 'trivial' shunt disappeared immediately in most
patients. In one-tenth of patients, a trivial residual
shunt was visible at discharge. Turbulance near the
device, which could not be clearly differentiated
from a minimal residual shunt, was observed in 5
additional patients.
While no rhythm disturbances occurred during
the period of follow-up, a transient alteration of
atrioventricular conduction was observed in 3
patients during the procedure, which resolved
immediately after unscrewing and repositioning of
the device. This impairment of atrioventricular
conduction seems to be due to mechanical destur-
bance of the atrioventricular node, which is com-
pressed between the umbrellas. The possibility to
relieve this mechanical alteration by unscrewing
and repositioning of the device seems to be an
advantage of the ASDOS-technique. In one addi-
tional patient, atrioventricular conduction deterio-
rated 6 hours after implantation, resulting in
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transient second to third degree atrioventricular
block. Although this resolved completely within 3
days, and remained normal during a follow-up
period of 26 months, this is potentially a serious
complication. Thus, care must be taken not to
implant oversized devices. In addition, we would
suggest, that in the region of the atrioventricular
node a residual rim of atrial tissue of at least 7 mm
should be present. As an estimate for the size of the
atrial septum, we measured the depth of the atri-
ums in the apical four chamber view. These data,
however, do not show wether this measure is ade-
quate for the selection of the largest possible
device. Rather careful echocardiographic monitor-
ing of the device during implantation and elucida-
tion of its relation to adjacent structures, is
mandatory.
As has been reported with other devices,19'27"29
one arm of the device fractured in four of our
patients (Fig.3). As it was impossible to visualize
fractures in the chest X-ray, the integrity of all
devices was controlled by fluoroscopy. This should
also be recommended for the follow up of other
devices. The fractured arms, and the device itself,
remained in an unchanged and stable position for
at least 19 months. In none of these patients did
residual shunting occur. This stability of the frac-
tured arms can be attributed to their curved shape,
which had been designed to prevent migration of
fragments in case of fractures. All of the fractures
occurred in the center of the device, where the
stresses are highest. It can be suggested that some
of these fractures resulted from overdistension of
the arms by a 'thick' muscular interatrial septum,
resulting in a concave deformation of the device.
Although nitinol, from which the arms of the
ASDOS-device are made, has a high flexibility,
overdistension can result in fatigue fractures (Figs 3
& 4). Bench testing of the device in an overdis-
tended configuration showed that the incidence of
fractures increases with the angle of overdistension
of the nitinol. As overdistension of the device
depends on the thickness of the atrial septum,
elongation of the thread could be a solution to pre-
vent such overdistension. The need for a variable
distance between the umbrellas according to the
individual anatomy of the interatrial septum seems
to be an important observation, as the stresses
which occur between the device and a 'thick' inter-
atrial septum or the aortic root have not been rec-
ognized as a potential problem for design of
devices.
Although fractures seem to be a matter of con-
cern, they could also be an advantage, as they
relieve the stresses between the device and the
heart. If these stresses are not relieved, they can
result in friction lesions, pressure necrosis, and in
perforation of the atrial wall. When oversized
devices are used, laceration of the ascending aorta
can lead to hemopericardium, with pericardial
tamponade even months after the implantation.19"22
These stresses seem to be a particular problem of
devices made from nitinol, as this metal will tend
to retain its original shape independent of the indi-
vidual anatomy of the heart. Although fractures
can be an advantage by relieving potential stresses
between heart and device, it is important that the
device remains in stable position when fractures
occur, and that the resulting fragments do not
migrate, perforate or lacerate adjacent structures
and embolize.719
Although repositioning, retrieval and firm
attachment of the device within the oval fossa are
advantages of the ASDOS-technique, the possibil-
ity of fatigue fractures, and of mechanical alter-
ations due to the tension between the two
umbrellas, have to be mentioned as possible disad-
vantages. A clear disadvantage of the ASDOS-
technique is the complex procedure required for
implantation using an veno-arterial guidewire cir-
cuit. On the other hand, this allows release of the
device from the delivery system while it is still
secured by the guidewire circuit. Establishing this
veno-arterial guidewire-circuit is a complex
maneuver, with the risk of an arterial puncture and
Figure 4.
Overdistension of the device due to a 'thick' muscular interatrial sep-
tum. The concave deformation of the device can result in fatigue frac-
tures of the arms. Bench testing showed that the fracture rate of the
nitinol arms increases with the overdistension.
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the potential risk of lacerating the mitral or aortic
valve. No complications due to this maneuver,
however, were observed in this series. The fluoro-
scopic time of 36 ± 17.0 min, and a total proce-
dure time of 173 ± 100 min, seem to be acceptable
during the initial phase for a complex interven-
tional procedure, but seem to be rather long for a
routine procedure.
In conclusion, our medium-term data show that
the ASDOS-technique can be used with a high effi-
cacy and safety for the trancatheter closure of
defects in the oval fossa in a carefully selected
group of children. As with other transcatheter
techniques, a residual rim of atrial tissue surround-
ing the defect is necessary for succes, limiting the
application of this particular technique. The dis-
tance between the umbrellas should be adjustable
to prevent stresses between the device and the
heart, stresses which can result in fractures of arms
due to overdistension of the nitinol. The technique
of implantation is complex and time consuming,
but offers additional safety as unscrewing and repo-
sitioning of the device is possible after release from
the delivery system so that overdistension of the
device and direct contact with critical structures
can be avoided. Although our follow-up covers
76.8 patient-years, with a mean follow-up period
of 23.0 ± 5.6 months (13 to 32 months), further
experience is needed with this, to assess ist long-
term safety, any possible long-term problems, and
the limitations of the technique.
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